With its sights set on growth, German diagnostics outfit Curetis AG has closed a $18.1 million Series B financing round with new investor Qiagen chipping in.
Hot on the trail of companion diagnostics partnerships, Qiagen is teaming up with pharma bigwig Novartis to develop tests for the company's drug portfolio.
Qiagen beat the Street's expectations during the third quarter, riding high on strong sales of its companion diagnostic products and the continued success of its next-generation tuberculosis blood test.
Genomics England has dropped two-thirds of the candidates to provide variant annotation and clinical interpretation services to the 100,000 Genomes Project after reviewing the first round of responses.
The global companion diagnostics market crossed the billion-dollar threshold in 2013 and is continuing to climb rapidly as healthcare systems tap into the value of testing which patients would benefit most from targeted treatments.
Qiagen aims to develop new tests to target blood cancer patients who would benefit most from a particular treatment that hits a specific gene mutation. The plan could lead to new companion diagnostic tests for related drugs now under development.
Qiagen received FDA approval on June 24 under a full PMA for an assay that monitors the viral load of cytomegalovirus (CMV), a common virus that can be fatal to weakened immune systems, in organ transplant patients.
Qiagen and Eli Lilly have joined forces for their fourth companion diagnostics project, building on the momentum of past collaborations to develop assay panels for cancer.
Qiagen and Eli Lilly have clicked well enough in previous companion diagnostics development projects that they're signing up for a fourth go-around.
Qiagen gained FDA approval for a companion diagnostic test that will help spot patients with metastatic colorectal cancer who might benefit most from Amgen's drug Vectibix. The regulatory milestone represents another advance in the Dutch company's growing focus on personalized medicine.